Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Cancers With DNA Repair-Deficiency
Interventions
DRUG

Olaparib

Olaparib 150 mg tablet

DRUG

Physician's choice

treatment according to current guidelines

DRUG

Trabectedin

Trabectedin 1.1mg/m² infusional solution

Trial Locations (9)

45147

Universitätsklinikum Essen, Essen

55131

Universitätsmedizin der Johannes-Gutenberg-Universität Mainz, Mainz

60590

Universitätsklinikum Frankfurt, Frankfurt

69120

National Center for Tumordiseases (NCT), Heidelberg

70376

Klinik Schillerhöhe, Stuttgart

72076

Universitätsklinikum Tübingen, Tübingen

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

81377

Klinikum der Universität München-Großhadern, München

01307

Medizinische Fakultät der TU Dresden, Dresden

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

PharmaMar

INDUSTRY

collaborator

German Cancer Research Center

OTHER

lead

National Center for Tumor Diseases, Heidelberg

OTHER